BR112013015396A2 - método para a preparação de 18f para uso em uma hreação de radiofluoração, reação de radiofluoração e cassete para a realização da reação de radiofluoração - Google Patents

método para a preparação de 18f para uso em uma hreação de radiofluoração, reação de radiofluoração e cassete para a realização da reação de radiofluoração

Info

Publication number
BR112013015396A2
BR112013015396A2 BR112013015396A BR112013015396A BR112013015396A2 BR 112013015396 A2 BR112013015396 A2 BR 112013015396A2 BR 112013015396 A BR112013015396 A BR 112013015396A BR 112013015396 A BR112013015396 A BR 112013015396A BR 112013015396 A2 BR112013015396 A2 BR 112013015396A2
Authority
BR
Brazil
Prior art keywords
radiofluorination reaction
radiofluorination
reaction
cassette
preparation
Prior art date
Application number
BR112013015396A
Other languages
English (en)
Other versions
BR112013015396B1 (pt
Inventor
Anders Svadberg
Dag M Evje
Liane Ochsenfeld
Ole Kristian Hjelstuen
Torild Wickstrom
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of BR112013015396A2 publication Critical patent/BR112013015396A2/pt
Publication of BR112013015396B1 publication Critical patent/BR112013015396B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B9/00—General methods of preparing halides
    • C01B9/08—Fluorides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112013015396-2A 2010-12-29 2011-12-21 Método para a preparação de 18f para uso em uma reação de radiofluoração, reação de radiofluoração e cassete para a realização da reação de radiofluoração BR112013015396B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061427839P 2010-12-29 2010-12-29
US61/427,839 2010-12-29
PCT/EP2011/073670 WO2012089594A1 (en) 2010-12-29 2011-12-21 Eluent solution

Publications (2)

Publication Number Publication Date
BR112013015396A2 true BR112013015396A2 (pt) 2016-09-20
BR112013015396B1 BR112013015396B1 (pt) 2021-11-03

Family

ID=45495902

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013015396-2A BR112013015396B1 (pt) 2010-12-29 2011-12-21 Método para a preparação de 18f para uso em uma reação de radiofluoração, reação de radiofluoração e cassete para a realização da reação de radiofluoração
BR112014015042-7A BR112014015042B1 (pt) 2010-12-29 2012-12-21 Composição farmacêutica, e, método para obter uma composição radiofarmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112014015042-7A BR112014015042B1 (pt) 2010-12-29 2012-12-21 Composição farmacêutica, e, método para obter uma composição radiofarmacêutica

Country Status (16)

Country Link
US (3) US11504430B2 (pt)
EP (2) EP2658831B1 (pt)
JP (1) JP6018581B2 (pt)
KR (3) KR102218263B1 (pt)
CN (2) CN103270004A (pt)
AU (1) AU2011351550B2 (pt)
BR (2) BR112013015396B1 (pt)
CA (1) CA2823063C (pt)
DK (3) DK2658831T3 (pt)
ES (2) ES2621950T3 (pt)
MX (1) MX363538B (pt)
PL (2) PL2658831T3 (pt)
PT (2) PT2793954T (pt)
RU (1) RU2608932C2 (pt)
SG (1) SG10201805198TA (pt)
WO (1) WO2012089594A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012089594A1 (en) * 2010-12-29 2012-07-05 Ge Healthcare Limited Eluent solution
JP2015501305A (ja) * 2011-10-19 2015-01-15 ピラマル イメージング ソシエテ アノニム Ｆ‐１８標識Ａβリガンドの改良された製造方法
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
RU2623163C2 (ru) * 2011-12-21 2017-06-22 ДжиИ ХЕЛТКЕР ЛИМИТЕД Композиция 18f- флуцикловина в цитратных буферах
GB201214220D0 (en) 2012-08-09 2012-09-19 Ge Healthcare Ltd Radiosynthesis
GB201221266D0 (en) 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201305687D0 (en) * 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process
EP3068747A1 (en) 2013-11-13 2016-09-21 GE Healthcare Limited Dual run cassette for the synthesis of 18f-labelled compounds
US9988336B2 (en) * 2014-03-18 2018-06-05 Mayo Foundation For Medical Education And Research Gaseous F-18 technologies
NL2014828B1 (en) * 2015-05-20 2017-01-31 Out And Out Chemistry S P R L Method of performing a plurality of synthesis processes of preparing a radiopharmaceutical in series, a device and cassette for performing this method.
JP6827709B2 (ja) * 2016-04-25 2021-02-10 日本メジフィジックス株式会社 ２−［１８ｆ］フルオロ−２−デオキシ−ｄ−グルコースの製造方法
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
JP7148121B2 (ja) * 2018-08-31 2022-10-05 国立大学法人北海道大学 放射性核種１８ｆの精製方法
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
JP7127164B2 (ja) * 2021-01-19 2022-08-29 日本メジフィジックス株式会社 ２－［１８ｆ］フルオロ－２－デオキシ－ｄ－グルコースの製造方法
CN113372399A (zh) * 2021-06-04 2021-09-10 江苏华益科技有限公司 一种氟[18f]脱氧葡糖注射液的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5425063A (en) 1993-04-05 1995-06-13 Associated Universities, Inc. Method for selective recovery of PET-usable quantities of [18 F] fluoride and [13 N] nitrate/nitrite from a single irradiation of low-enriched [18 O] water
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
RU2165266C1 (ru) 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
EP1356827A1 (en) 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
WO2004043497A1 (en) 2002-11-05 2004-05-27 Ion Beam Applications S.A. Stabilzation of radiopharmceuticals labeled with 18-f
GB0422004D0 (en) * 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
GB0425501D0 (en) 2004-11-19 2004-12-22 Amersham Plc Fluoridation process
US7235216B2 (en) * 2005-05-01 2007-06-26 Iba Molecular North America, Inc. Apparatus and method for producing radiopharmaceuticals
GB0524851D0 (en) * 2005-12-06 2006-01-11 Ge Healthcare Ltd Radiolabelling method using polymers
AU2007262786B2 (en) * 2006-06-21 2012-12-06 Ge Healthcare Limited Radiopharmaceutical products
JPWO2008056481A1 (ja) 2006-11-09 2010-02-25 日本メジフィジックス株式会社 放射性画像診断剤
CN101563107B (zh) 2006-12-21 2012-07-11 日本医事物理股份有限公司 放射性诊断显像剂
EP2119458B9 (en) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
EP2017359A3 (en) * 2007-06-11 2009-08-05 Trasis S.A. Method for the elution of 18F fluoride trapped on an anion-exchange resin in a form suitable for efficient radiolabeling without any evaporation step
KR101009712B1 (ko) * 2007-02-22 2011-01-19 재단법인 아산사회복지재단 양성자성 용매와 이에 녹는 염들을 이용한 음이온 교환고분자 지지체로부터의 플루오린-18 플루오라이드 용리와이를 이용한 플루오린-18의 표지방법
US20100150835A1 (en) 2007-02-27 2010-06-17 Bengt Langstrom Synthesis of [18F] Fluoromethyl Benzene Using Benzyl Pentafluorobenzenesulfonate
EP1990310A1 (en) * 2007-04-23 2008-11-12 Trasis S.A. Method for the preparation of reactive 18F fluoride, and for the labeling of radiotracers, using a modified non-ionic solid support and without any evaporation step
WO2009045535A2 (en) * 2007-10-04 2009-04-09 Sloan-Kettering Institute For Cancer Research Fluorine-18 derivative of dasatinib and uses thereof
ES2610574T3 (es) 2007-12-19 2017-04-28 Nihon Medi-Physics Co., Ltd. Procedimiento para producir un compuesto orgánico marcado con flúor radiactivo
US20090171272A1 (en) 2007-12-29 2009-07-02 Tegg Troy T Deflectable sheath and catheter assembly
EP2238074A2 (en) * 2008-01-03 2010-10-13 GE Healthcare UK Limited Fluoride processing method
EP2110367A1 (en) * 2008-04-14 2009-10-21 Bayer Schering Pharma Aktiengesellschaft Purification strategy for direct nucleophilic procedures
GB0819293D0 (en) 2008-10-21 2008-11-26 Hammersmith Imanet Ltd Radiofluorination
US20110250137A1 (en) * 2008-12-04 2011-10-13 Bayer Schering Pharma Aktiengesellchaft Radioisotope-labeled lysine and ornithine derivatives, their use and processes for their preparation
TW201033713A (en) 2009-03-03 2010-09-16 Wintek Corp Reflective color-changing liquid crystal display
SI2579902T2 (sl) * 2010-06-04 2019-10-30 Life Molecular Imaging Sa Postopek za izdelavo amiloidnih beta ligandov, označenih s F-18
WO2012089594A1 (en) * 2010-12-29 2012-07-05 Ge Healthcare Limited Eluent solution
GB201214220D0 (en) * 2012-08-09 2012-09-19 Ge Healthcare Ltd Radiosynthesis

Also Published As

Publication number Publication date
RU2013126979A (ru) 2015-03-20
DK2793954T3 (da) 2021-01-04
PT2793954T (pt) 2021-01-06
AU2011351550A1 (en) 2013-07-25
CN103270004A (zh) 2013-08-28
BR112013015396B1 (pt) 2021-11-03
JP6018581B2 (ja) 2016-11-02
KR102137348B1 (ko) 2020-07-23
MX2013007699A (es) 2013-08-15
EP2658831A1 (en) 2013-11-06
DK2658831T3 (en) 2017-04-24
BR112014015042A8 (pt) 2017-07-04
AU2011351550B2 (en) 2017-02-02
BR112014015042B1 (pt) 2021-10-26
US20130324715A1 (en) 2013-12-05
KR20130132892A (ko) 2013-12-05
BR112014015042A2 (pt) 2017-06-13
PT3766522T (pt) 2022-06-14
US20190192660A1 (en) 2019-06-27
MX363538B (es) 2019-03-27
ES2917875T3 (es) 2022-07-12
EP3766522B1 (en) 2022-03-23
WO2012089594A1 (en) 2012-07-05
CN108218650A (zh) 2018-06-29
KR20190119673A (ko) 2019-10-22
ES2621950T3 (es) 2017-07-05
PL3766522T3 (pl) 2022-07-04
PL2658831T3 (pl) 2017-07-31
JP2014508731A (ja) 2014-04-10
US11504430B2 (en) 2022-11-22
KR102218263B1 (ko) 2021-02-22
SG10201805198TA (en) 2018-07-30
RU2608932C2 (ru) 2017-01-26
US20230068052A1 (en) 2023-03-02
KR20190008994A (ko) 2019-01-25
EP3766522A1 (en) 2021-01-20
CA2823063A1 (en) 2012-07-05
CA2823063C (en) 2020-08-11
DK3766522T3 (da) 2022-06-13
EP2658831B1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
BR112013015396A2 (pt) método para a preparação de 18f para uso em uma hreação de radiofluoração, reação de radiofluoração e cassete para a realização da reação de radiofluoração
IL251600A0 (en) En-ethyl-en-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide containing deuterium, and salts and uses of the substance
HK1226068A1 (zh) 特定氨基-嘧啶、其組合物及其使用方法
HK1174030A1 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
HK1168584A1 (zh) 種新的丹酚酸化合物 、其製備方法和用途
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
EP2560488A4 (en) CERTAIN AMINOPYRIMIDINES AND AMINOTRIAZINES, COMPOSITIONS AND METHOD FOR THEIR USE
EP2659966A4 (en) PT / GRAPHENE CATALYST, PREPARATION METHOD AND USE THEREOF
ZA201300957B (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof
EP2530079A4 (en) PHENYL-C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BR112014013057A8 (pt) método para síntese de compostos, e, cassete para realizar o método
EP2573072A4 (en) INDENOQUINOLONE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
BR112013013285A2 (pt) agente de formação de imagem, precursor, métodos de preparação do agente de formação de imagem, e de formação de imagem, composição radiofarmacêutica, kit para a preparação da composição radiofarmacêutica, e, uso do agente de formação de imagem
BR112013003385A2 (pt) "composições e métodos para produzir células dentríticas"
IL226003A0 (en) Derivation of trans-2-decenoic acid and a pharmaceutical agent containing it
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR112013014817A2 (pt) composições orais e métodos para produção das mesmas
EP2634184A4 (en) C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
BR112013013415A2 (pt) composição farmacêutica, e, método para a preparação de uma composição
BR112012011915A2 (pt) composição; substância anfifílica, processo para a preparação da substância anfifílica e processo para a preparação da composição
BR112013014675A2 (pt) composições orais e métodos para produção das mesmas
HK1182693A1 (en) Theanine derivative, preparation method thereof, and use thereof for alleviating acne
EP2626702A4 (en) DIAGNOSIS, DIAGNOSTIC PROCEDURE AND THERAPEUTIC AGENT FOR FIBROMYALGIA

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2011, OBSERVADAS AS CONDICOES LEGAIS.